Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Stuart A. Ross; Elizabeth Rafeiro; Thomas Meinicke; Robert Toorawa; Sonja Weber-Born; Hans-Juergen Woerle

doi:10.1185/03007995.2012.714360

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Current Medical Research and Opinion ◽

10.1185/03007995.2012.714360 ◽

2012 ◽

Vol 28 (9) ◽

pp. 1465-1474 ◽

Cited By ~ 30

Author(s):

Stuart A. Ross ◽

Elizabeth Rafeiro ◽

Thomas Meinicke ◽

Robert Toorawa ◽

Sonja Weber-Born ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Diabetes Care ◽

10.2337/dc11-1935 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1225-1231 ◽

Cited By ~ 154

Author(s):

V. A. Fonseca ◽

R. Alvarado-Ruiz ◽

D. Raccah ◽

G. Boka ◽

P. Miossec ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2012.01662.x ◽

2012 ◽

Vol 14 (11) ◽

pp. 1040-1046 ◽

Cited By ~ 51

Author(s):

T. Eto ◽

S. Inoue ◽

T. Kadowaki

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Blood Glucose Control ◽

Japanese Patients ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Diabetic Medicine ◽

10.1111/j.1464-5491.2010.03020.x ◽

2010 ◽

Vol 27 (9) ◽

pp. 1024-1032 ◽

Cited By ~ 108

Author(s):

R. E. Ratner ◽

J. Rosenstock ◽

G. Boka ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Cited By ~ 308

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients with Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism ◽

10.31031/gjem.2018.02.000543 ◽

2018 ◽

Vol 2 (4) ◽

Author(s):

Davis Townsend

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review3 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text